• Discovered by Brian Sathianathan
Claim this
Startup
Write to the

About Annexon

Annexon is developing drugs to inhibit the complement cascade, which the company believes is a key mechanism in neurodegenerative diseases. These drugs are expected to halt the progression of these ...

Sample startup success signal Increased Conversion Rate By

50.0%

Verified by Iterate and ASD IT
Posted by Jon Nordmark,
CEO at Iterate.ai,
June, 2016

Annexon describes itself with 3 words or categories

Health CarePharmaceuticalsBiotechnology

Solutions offered by Annexon

Video

Presentation

Case Study

Competitive Landscape

Capitalization

  • #DATA_YEAR# : $
    #NAME#
    from #DATA_FROM#
  • News

    No news added yet.

    Company Size

    1-10 employees